Previous 10 | Next 10 |
Metacrine (NASDAQ:MTCR) has announced the resignation of Chief Medical Officer (CMO) Hubert Chen. Chen will step down effective December 31, 2021. Metacrine CEO Preston Klassen is likely to assume responsibility for the company's ongoing clinical trials and future clinical operations. MTCR...
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to...
Gainers: Society Pass Incorporated Common SOPA +260%. Bluerock Residential Growth REIT BRG +71%. Can-Fite BioPharma CANF +67%. Galera Therapeutics (NASDAQ:GRTX) +42%. AeroClean Technologies. (NASDAQ:AERC) +38%. Losers: Summit Therapeutics SMMT -...
Gainers: Society Pass (NASDAQ:SOPA) +237%. Bluerock Residential Growth (NYSE:BRG) +71%. Can-Fite (NYSE:CANF) +59%. AeroClean (NASDAQ:AERC) +58%. Galera Therapeutics (NASDAQ:GRTX) +38%. Verso (NYSE:VRS) +35%. Roivant (NASDAQ:ROIV) +26%. Venus (NASDAQ:VERO) +25%. BioCardia (NASDAQ:BCDA) +1...
GAINERS: SK Telecom (NYSE:SKM) +74%. Genfit (NASDAQ:GNFT) +59%. Spruce Biosciences (NASDAQ:SPRB) +54%. Stran & Company. Warrant (NASDAQ:STRNW) +34%. Bellerophon Therapeutics (NASDAQ:BLPH) +31%. LOSERS: Pasithea Therapeutics (NASDAQ:KTTA) -17%. Metacrine (N...
Fed Chair Jerome Powell took the podium this afternoon following a 2-day FOMC meeting. Reiterating improving labor conditions and maximum employment thanks to job gains over the last few months, markets turned green on Wednesday afternoon. At the same time, the Fed’s ramp-up of taper...
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results. “Our recent...
- Validates therapeutic benefit of combination approaches for a large segment of NASH patients - Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clin...
The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as b...
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the effi...
News, Short Squeeze, Breakout and More Instantly...
Metacrine Inc. Company Name:
MTCR Stock Symbol:
NASDAQ Market:
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...